These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 6388070

  • 21. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation.
    Rostaing L, Chabannier MH, Modesto A, Rouzaud A, Cisterne JM, Tkaczuk J, Durand D.
    Am J Nephrol; 1999; 19(6):634-40. PubMed ID: 10592356
    [Abstract] [Full Text] [Related]

  • 22. Rejection monitoring by lymphocyte blastogenesis assay in canine lung allotransplantation.
    Fujimura S, Kondo T, Yamauchi A, Okabe T, Handa M, Shionozaki F, Saito R, Horikawa M, Nakada T.
    Tohoku J Exp Med; 1984 Mar; 142(3):321-35. PubMed ID: 6233754
    [Abstract] [Full Text] [Related]

  • 23. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
    Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O'Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, Thistlethwaite JR.
    Transplantation; 1999 Sep 15; 68(5):608-16. PubMed ID: 10507477
    [Abstract] [Full Text] [Related]

  • 24. Successful retreatment of allograft rejection with OKT3.
    First MR, Schroeder TJ, Hurtubise PE, Mansour ME, Penn I, Munda R, Balistreri WF, Alexander JW, Melvin DB, Fidler JP.
    Transplantation; 1989 Jan 15; 47(1):88-91. PubMed ID: 2521410
    [Abstract] [Full Text] [Related]

  • 25. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients.
    Waid TH, Lucas BA, Thompson JS, Brown SA, Munch L, Prebeck RJ, Jezek D.
    Transplantation; 1992 Jan 15; 53(1):80-6. PubMed ID: 1531095
    [Abstract] [Full Text] [Related]

  • 26. Therapeutic strategies in immunosuppression after renal transplantation.
    Morris PJ.
    J Pediatr; 1987 Dec 15; 111(6 Pt 2):1004-7. PubMed ID: 3316571
    [Abstract] [Full Text] [Related]

  • 27. Delayed response to orthoclone OKT3 treatment for renal allograft rejection resistant to steroid and antilymphocyte globulin.
    Oh CS, Sollinger HW, Stratta RJ, Kalayoglu M, Belzer FO.
    Transplantation; 1988 Jan 15; 45(1):65-7. PubMed ID: 3276065
    [Abstract] [Full Text] [Related]

  • 28. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection.
    Norman DJ, Shield CF, Henell KR, Kimball J, Barry JM, Bennett WM, Leone M.
    Transplantation; 1988 Oct 15; 46(4):523-9. PubMed ID: 3140448
    [Abstract] [Full Text] [Related]

  • 29. Mobilization of T lymphocytes following cardiac transplantation. Evidence that CD4-positive cells are required for cytotoxic T lymphocyte activation, inflammatory endothelial development, graft infiltration, and acute allograft rejection.
    Bishop DK, Shelby J, Eichwald EJ.
    Transplantation; 1992 Apr 15; 53(4):849-57. PubMed ID: 1533070
    [Abstract] [Full Text] [Related]

  • 30. Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody.
    Gilbert EM, Dewitt CW, Eiswirth CC, Renlund DG, Menlove RL, Freedman LA, Herrick CM, Gay WA, Bristow MR.
    Am J Med; 1987 Feb 15; 82(2):202-6. PubMed ID: 3544838
    [Abstract] [Full Text] [Related]

  • 31. Acute renal allograft rejection: the role of monoclonal antibodies in treatment: experience with orthoclonal anti-T3 cell antibody.
    McLigeyo SO, Notghi A, Anderton JL, Dick J.
    East Afr Med J; 1990 Sep 15; 67(9):667-73. PubMed ID: 2123786
    [Abstract] [Full Text] [Related]

  • 32. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L, Narvarte J, Ackermann J, LeFor W, Weinstein S, Wright C, deQuesada A, Baxter J, Shires D.
    Am J Kidney Dis; 1989 Nov 15; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [Abstract] [Full Text] [Related]

  • 33. Monoclonal antibody (OKT3) rescue in refractory acute renal allograft rejection: report of 3 cases.
    Suvanapha R, Laorpatanaskul S, Vajaraphongse R, Kitisin P, Srivatanawongsa V, Mulikamas S, Vajaraphongse K, Boonvisut S, Chusil S, Panmuong W.
    J Med Assoc Thai; 1989 Dec 15; 72(12):708-13. PubMed ID: 2628539
    [Abstract] [Full Text] [Related]

  • 34. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW, Jendrisak MD, So SK, McCullough CS, Rush TM, Michalski SM, Phelan D, Mohanakumar T.
    Transplantation; 1994 Feb 15; 57(3):377-84. PubMed ID: 8108873
    [Abstract] [Full Text] [Related]

  • 35. The kinetics of tolerance induction by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus intravenous donor alloantigen administration.
    Motoyama K, Arima T, Yu S, Lehmann M, Flye MW.
    Transplantation; 2000 Jan 27; 69(2):285-93. PubMed ID: 10670640
    [Abstract] [Full Text] [Related]

  • 36. Development of specific nonreactivity in human cadaveric renal allograft recipients.
    Sengar DP, Rashid A, Harris JE.
    Tissue Antigens; 1976 May 27; 7(5):281-90. PubMed ID: 132717
    [Abstract] [Full Text] [Related]

  • 37. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
    Waid TH, Lucas BA, Thompson JS, McKeown JW, Brown S, Kryscio R, Skeeters LJ.
    Transplantation; 1997 Jul 27; 64(2):274-81. PubMed ID: 9256187
    [Abstract] [Full Text] [Related]

  • 38. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function.
    Cohen DJ, Benvenisty AI, Cianci J, Hardy MA.
    Am J Kidney Dis; 1989 Nov 27; 14(5 Suppl 2):19-27. PubMed ID: 2510507
    [Abstract] [Full Text] [Related]

  • 39. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative clinical trials in transplantation pilot study. Cooperative Clinical Trials in Transplantation Research Group.
    Transplantation; 1997 May 15; 63(9):1243-51. PubMed ID: 9158016
    [Abstract] [Full Text] [Related]

  • 40. OKT3 monoclonal antibody reversal of renal and hepatic rejection in pediatric patients.
    Goldstein G, Kremer AB, Barnes L, Hirsch RL.
    J Pediatr; 1987 Dec 15; 111(6 Pt 2):1046-50. PubMed ID: 3316579
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.